| HZ-0046 | Potential or stored energyCompression | Intended Use | - 1. Neointimal hyperplasia develops within the stented segment over weeks to months
- 2. Neointimal tissue compresses the stent lumen, progressively reducing coronary blood flow
| Normal | 4 | Patient coronary artery lumen progressively narrowed by neointimal tissue growth within the stented segment | 3 | Myocardial ischemia | 4 | 3 | High | - 1. Design
- 2. Information for Safety
| - •PR-0001-004: Stent surface finish optimized to minimize thrombogenicity and neointimal hyperplasia response
- •PR-0006-002: IFU recommends post-procedural antiplatelet therapy and clinical follow-up to monitor for restenosis
| - CP-00024 Surface finish and biocompatibility specification, Component
- IFU0010, Instructions for Use
| - TR-00073 Surface roughness measurement
- TR-00074 Hemocompatibility test
- TR-00075 Labeling review for follow-up recommendations
| TBD | TBD | Myocardial ischemia | TBD | | | N |
|---|
| HZ-0109 | DeliveryRate | Misuse: Use Error | - 1. Balloon inflation rate exceeds the recommended range
- 2. Stent expands asymmetrically against the vessel wall
| Fault | 2 | Patient coronary artery wall subjected to asymmetric radial force during stent deployment | 3 | Coronary dissection | 4 | 2 | Medium | - 1. Information for Safety
| - •PR-0006-005: IFU specifies recommended balloon inflation rate and technique to achieve uniform stent expansion
| - IFU0010, Instructions for Use
| - TR-00185 Human factors validation of deployment procedure instructions
| TBD | TBD | Coronary dissection | TBD | | | N |
|---|
| HZ-0072 | Biological agentsViruses | Intended Use | - 1. Viral contamination persists on raw material or manufacturing environment surface
- 2. Terminal sterilization process fails to achieve adequate viral inactivation
| Fault | 1 | Patient bloodstream exposed to viral agents on stent surface during coronary implantation | 2 | Viral infection | 4 | 1 | Medium | - 1. Process
| - •PR-0003-006: Manufacturing environment controlled per ISO 14644 cleanroom classification with validated cleaning and disinfection procedures.
- •PR-0003-007: Incoming raw material supplier qualification includes viral safety assessment.
| - TBD by client Cleanroom environmental control work instruction, Work Instruction
- TBD by client Supplier qualification procedure for raw materials, Work Instruction
| - TR-00121 Environmental monitoring and particulate count validation
- TR-00122 Supplier audit and certificate of analysis review
| TBD | TBD | Viral infection | TBD | | | N |
|---|
| HZ-0064 | Chemical agents - pyrogenicPyrogenic | Intended Use | - 1. Pyrogenic material contaminates stent surface during manufacturing
- 2. Terminal sterilization fails to eliminate non-endotoxin pyrogenic substances
| Fault | 2 | Patient bloodstream exposed to pyrogenic material on stent surface during coronary implantation | 3 | Fever | 2 | 2 | Low | - 1. Process
- 2. Design
| - •PR-0003-003: Material-mediated pyrogen testing per ISO 10993-11 or USP <151> on finished stent.
- •PR-0003-004: Manufacturing process includes validated depyrogenation step for stent components.
| - TBD by client Pyrogen testing work instruction, Work Instruction
- CP-00030 Depyrogenation process specification, Component
| - TR-00104 Pyrogen test per ISO 10993-11
- TR-00105 Depyrogenation efficacy validation
| TBD | TBD | Fever | TBD | | | N |
|---|